A Label-free Extracellular-vesicle Automated Purification System (LEAP System)

Information

  • Research Project
  • 10324624
  • ApplicationId
    10324624
  • Core Project Number
    R43GM144009
  • Full Project Number
    1R43GM144009-01
  • Serial Number
    144009
  • FOA Number
    PA-20-260
  • Sub Project Id
  • Project Start Date
    9/1/2021 - 2 years ago
  • Project End Date
    2/28/2022 - 2 years ago
  • Program Officer Name
    KREPKIY, DMITRIY
  • Budget Start Date
    9/1/2021 - 2 years ago
  • Budget End Date
    2/28/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
  • Award Notice Date
    8/18/2021 - 2 years ago

A Label-free Extracellular-vesicle Automated Purification System (LEAP System)

PROJECT SUMMARY / ABSTRACT Extracellular vesicles (EVs) are small lipid bilayer particles secreted by most cell types, which encapsulates biomolecules including lipids, proteins, and nucleic acids from parent cells. Profiling of EV-derived biomarkers provides a promising approach for early diagnoses and prognosis of various diseases. Currently, one of the primary hindrances to the implementation and usage of EVs is lack of a robust method for convenient and high- speed isolation of EVs with high yield and purity. A number of recent publications mentioned that developing efficient and reliable isolation methods is urgent to further advance in this field. There is a strong desire to explore innovated technologies for better performance of EV isolation in terms of throughput, purity, yield, speed, robustness, and cost. To overcome these challenges, WellSIM Biomedical Technologies proposes to develop, optimize, and validate a Label-free Extracellular-vesicle Automated Purification System (LEAP System) for EV isolation from bodily fluids (e.g., plasma and urine) with excellent performance. Based on our current prototype which has shown competitive EV yield, purity, and isolation efficiency, we will further improve the processing speed, sample volume load, and throughput by redesigning and optimizing the System. Our preliminary studies support that, with the proposed improvement, we can expect to simultaneously isolate EVs from up to 6 plasma samples (>2 mL) within 1 hr with purity and yield outperform other EV isolation methods. After system upgrade and optimization, we will comprehensively validate our next-generation platform with cell culture medium, urine, and plasma in terms of yield, purity, speed, and processing volume. Our new platform will directly address the current bottlenecks, and thus provide an advanced EV purification tool for EV-based life science and precision medicine.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    197500
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
  • Funding ICs
    NIGMS:197500\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    WELLSIM BIOMEDICAL TECHNOLOGIES, INC.
  • Organization Department
  • Organization DUNS
    081096834
  • Organization City
    Berkeley
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    94710
  • Organization District
    UNITED STATES